22 March - 25 March 2021

Join us at US BEBPA

We are delighted to be joining the virtual 5th Annual US Bioassay Conference as a Rapid Fire Presenter on Monday, 22 March, 11:20-12:00 PST!

22 March - 25 March 2021

Join us at US BEBPA

We are delighted to be joining the virtual 5th Annual US Bioassay Conference as a Rapid Fire Presenter on Monday, 22 March, 11:20-12:00 PST!

Join our live discussion

Welcome to the live roundtable discussion with the topic “Solutions for Potency Assays” 

Monday, 22 March, 11:20-12:00 PST (19:20-20:00 CET)

The live “Solutions for Potency Assays” roundtable discussion provides an opportunity to listen to three rapid fire presentations with leading experts - and there will be a Q&A at the end of the session.

Don't miss the opportunity to listen to our own Dr. Michael Tovey, Managing Director of Svar Life Science France, who will present “Quantification of Bevacizumab Activity Following Treatment of Patients with Ovarian Cancer or Glioblastoma”

It is a study that was carried out recently in patients with ovarian cancer or glioblastoma treated with bevacizumab the results of which illustrate the utility of our VEGF-responsive and VEGF-specific ADCC assays to monitor the response of patients to therapy.

Join BEBPA and our zoom room to hear him speak!


Book an exclusive meeting and tailored consultation with our team of experts!

The BioPharmaceutical Emerging Best Practices Association (BEBPA) is managed by, and for the benefit of, the biopharmaceutical scientific community.

BEBPAs' aim is to promote development of innovative approaches and solutions to facilitate safer and faster biopharmaceutical product development.

It provides an international forum for the presentation and discussion of scientific issues, and problems, encountered in the biopharmaceutical community.